ILXQuant Obesity and Metabolic Health Basket Index

Fixed-basket index of 10 companies at the centre of the GLP-1 obesity drug revolution -- originators (Novo Nordisk, Eli Lilly), next-generation oral challengers (Viking Therapeutics, Structure Therapeutics), competing platforms (Amgen), telehealth distribution (Hims and Hers), continuous glucose monitoring (DexCom), rare obesity (Rhythm Pharmaceuticals), and liver/metabolic disease (Madrigal, Tern). Rebalances quarterly to equal weight. GLP-1 drugs are on track to become the largest-revenue drug category in history with benefits extending beyond weight loss.

Index identifier
ILXGLP
Category
Basket
Universe
Fixed basket -- 10 obesity and metabolic health companies (equal weight)
Currency
USD
Inception
2023-03-06
Rebalancing
Quarterly (first Monday of March, June, September, December)
Index fee
0.60% p.a.
Reference benchmark
Health Care SPDR (XLV)

Performance and risk

All figures below are measured over a trailing window of up to 1,260 trading days (approximately five years), not since index inception.

Performance and risk — 2023-03-06 to 2026-08-13 00:00:00
Annualised return+54.98%
Sharpe ratio1.54
Calmar ratio1.64
Volatility35.77%
Maximum drawdown-33.44%
Return, 1 month
Return, 3 months
Return, 1 year
Return, year to date+2.49%

Full performance history, drawdown analysis, rolling risk metrics and portfolio breakdowns for this index are available in the ILX Quant platform.